BioLineRx vs Rafael
BLRX and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLRX and RFL compare
Rafael grew revenue faster over the last twelve months (−4.7% versus −95.9% for BioLineRx).
Rafael scores higher on the StockData Score (5 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLRX | RFL |
|---|---|---|
| Size and price | ||
| Market cap | – | $47.7M |
| Share price | $1.12 | $0.913 |
| Change, 1 year | −65.3% | −25.1% |
| Change, 5 years | −98.9% | −84.5% |
| Beta (5Y) | 1.56 | 0.58 |
| Employees | 20 | 17 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 54.5× |
| P/B | – | 0.7× |
| FCF yield | – | −62.9% |
| Growth | ||
| Revenue growth (TTM) | −95.9% | −4.7% (better) |
| Revenue growth, 5Y average | – | 1.7% |
| Profitability | ||
| Gross margin | 80.5% | – |
| Operating margin | −872% (better) | −3823% |
| Net margin | – | −3391% |
| FCF margin | −686% (better) | −3431% |
| Return on equity | – | −36.9% |
| Return on invested capital | −59.7% (better) | −61.5% |
| Financial health | ||
| Debt / equity | 0.33 | – |
| Interest coverage | −8.0× (better) | −100.3× |
| Current ratio | 1.20 | 2.35 (better) |
| Altman Z-score | – | −2.94 |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 7.5% |
| Held by insiders | 0.39% | 39.2% |
| Short interest, % of float | – | 0.92% |
Go deeper
- BLRX stock overview
- BLRX income statement
- BLRX valuation and score
- RFL stock overview
- RFL income statement
- RFL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.